Mogamulizumab, designated as KW-0761 and bearing the registration number 1159266-37-1, represents a distinct approach to managing cutaneous T-cell lymphoma (CTCL). This recombinant monoclonal immunoglobulin https://www.targetmol.com/compound/mogamulizumab